Abstract
Foxm1 is a potential transcription factor that is abundantly expressed in highly proliferative human lung cancer cells. Foxm1 also strongly correlates to lung fibrosis, epithelial-mesenchymal transition (EMT) to enhance metastatic program during the lung adenocarcinoma development. Foxm1 plays a pivotal role in controlling cell cycle phase through the G1-S-G2 checkpoint. The increasing Foxm1 and K-ras oncogene expression significantly associate with tumor growth and poor prognosis that potentially modulate patient's mortality in a subject with lung carcinoma. The genetic evidence showed that the silencing of Foxm1 resulted in the decrease in lung tumorigenesis. Thus, Foxm1 may contribute in the future as the potential target for cancer therapy by reducing lung fibrosis, EMT, and tumor cell proliferation to improve patient's survival rate.